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Information regarding the probability of ﬁnding HLA-matched related donor for a patient awaiting hema-
topoietic stem cell transplantation (HSCT) in developing countries is scanty. We performed a retrospective
review of HLA genotypes and related data for 1254 consecutive patients and their families at King Hussein
Cancer Center in Amman, Jordan, between 2003 and 2011 to evaluate the chance of ﬁnding HLA-matched
donor. The median family size was 5 for all patients in the study (range, 1-14), and the average number of
donors was 1.4  0.9 for pediatric patients and 1.6  0.9 for adults. Overall, the probability of ﬁnding an HLA-
matched related donor at our center was 65.5% (60.6% in pediatric patients and 74% in adults). Of the total
identiﬁed donors, 18% were nonsibling donors after an immediate and/or extended family search in the
pediatric group, and 6% were nonsibling donors in the adult group. Overall, 13% of donors were nonsibling
donors. We conclude that the probability of ﬁnding a matched related donor for HSCT in Jordan is much
higher than that reported in Western countries and Asia (65% versus 25%). We expect a similar trend in other
developing and Arab countries. We recommend integrating an extended family search before or concomi-
tantly with an unrelated donor search.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION donors. We also report the prevalence of HLA phenotypes in
Allogenic hematopoietic stem cell transplantation (HSCT)
is the sole curative therapy available for many life-
threatening malignant and nonmalignant disorders. Donor
selection is a key component of the clinical practice of
transplantation, with HLA-identical siblings the preferred
donors [1]. In Western countries, approximately one-third of
the patients in need of HSCT have HLA-identical siblings [2].
The common procedure in a search for an HLA-matched
donor is to ﬁrst examine the patient’s siblings and parents.
The best chance of ﬁnding a matched donor is within the
nuclear family, followed by extended family.
The Middle Eastern region, including Arabic developing
countries, consists of communities of large families with high
population growth and density and many consanguineous
marriages, which certainly increase the likelihood of ﬁnding
a fully HLA-matched sibling donor. For example, the reported
likelihood of ﬁnding a fully matched sibling donor is 60% in
Saudi Arabia [3] and as high as 70% in some areas of Pakistan
[4], much higher than the likelihood reported in European
and North American patients [2]. In Jordan, the average
number of children per family was once 5.6, but has dropped
to 3.3 in the last ﬁfteen years [5]. Recent data show a decline
in consanguineous marriage among Jordanians from 63.7%
[6] to 49%, in the last ﬁfteen years with ﬁrst-cousinmarriages
the most predominant type [7].
Limited data are available regarding the likelihood of
having a matched related donor in developing and Arab
countries. The aims of the present study were to evaluate the
chance of ﬁnding a matched HLA-identical donor for Jorda-
nian patients requiring HSCT and to determine the relevance
of an extended family search in identifying matched relateddgments on page 225.
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PATIENTS AND METHODS
DonoreRecipient Matching
A total of 1254 patients were consecutively tested at the Molecular
Diagnostics and Immunogenetics Laboratory of King Hussein Cancer Center
(KHCC) between January 2003 and December 2011. Characteristics of these
1254 patients are summarized in Table 1. The patient ﬁles were retrospec-
tively screened for HLA class I and class II low-resolution typing of the
patients and potential donors. Donors and recipients were antigen-matched
(6/6) at the HLA-A, -B, and -DR loci through the HLA genotyping method-
ology described below. Demographic and clinical data were collected from
the patients’ medical ﬁles.
To better deﬁne the source of donors, we distinguished the matched
sibling donors from nonsibling donors, with the latter including immediate
family (ie, parents) and extended family (ie, any other related family
member, eg, ﬁrst cousins and blood-related uncles and aunts) who could be
a potential donor. An extended family search was pursued in cases where
the parents were close relatives (ie, consanguineous marriage); thus, blood-
related uncles and aunts were considered likely donor candidates. Alter-
natively, in cases where 2 married individuals each from a patient’s paternal
or maternal side were identiﬁed, then HLA typing was performed in their
offspring (ie, the patient’s cousins).
HLA Genotyping
HLA typing was done with PCResequence-speciﬁc primers (PCR-SSPs)
using a MicroSSP Generic HLA Class I and Class II ABDR DNA Typing Tray
(One Lambda, Canoga Park, CA). In brief, DNAwas extracted from peripheral
blood collected in EDTA tubes using a Gentra Puregene Blood Kit (Qiagen,
Crawley, UK) according to the manufacturer’s instructions. DNA quantity
was assessed with a NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientiﬁc, Waltham, MA), and purity was evaluated by calculating the 260/
280 ratio. All DNA was stored at 20C until testing. Data were interpreted
using the worksheets provided by the manufacturer. HLA-A, -B, and -DR
high-resolution typing was routinely applied when identity could not be
ascertained by descent and when evaluating nonsibling donors. Donors
with the best matching type and the highest resolution available were
selected for conﬁrmatory typing.
Allele Frequency Determination
Allele frequencies were calculated by dividing the total number of
occurrences of that allele by the total number of alleles at that locus in the
population, as described previously [8].Transplantation.
Table 1
Descriptive Patient Data
All Patients Pediatric Adult
Total number 1254 815 (65) 439 (35)
Age group, years, n (%)
0-5 246 (30)
6-12 364 (45)
13-18 205 (25)
18-35 262 (60)
36-50 131 (30)
>50 years 46 (10)
Sex, n (%)
Male 735 (58.6) 469 (57.5) 266 (61)
Female 519 (41.4) 346 (42.5) 173 (39)
Disease, n (%)
Malignant 685 (56) 320 (39) 385 (87.7)
Nonmalignant 535 (44) 495 (61) 54 (12.3)
Donor availability, n (%)
Donor 821 (65.5) 494 (60.6) 327 (74)
No donor 433 (34.5) 321 (39.4) 112 (26)
Donor status, n (%)
Sibling 715 (87) 407 (82) 308 (94)
Nonsibling related 106 (13) 87 (18) 19 (6)
Immediate family 85 (80) 72 (83) 13 (68)
Extended family 21 (20) 15 (17) 6 (32)
Table 2
Patient Family Size and Donor Data in All Subgroups
Value
Family size, median (range)
All patients 5 (1-14)
Patients with donors 5 (1-13)
Patients with sibling donors 5 (1-13)
Patients with nonsibling donors 4 (1-13)
Patients without donors 4 (1-14)
Donor availability, median (range)
All patients 1 (1-7)
Patients with sibling donors 1 (1-6)
Patients with nonsibling donors 1 (1-4)
Patients with extended family donors 1 (1-7)
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All patient and donor data was entered into an Excel spreadsheet
(Microsoft, Redmond, WA). Counts, percentages, and medians are provided
for basic data description purposes. For some tables, data are summarized
by mean  SD for continuous variables and by number and percentage
for categorical variables. The probability of ﬁnding a matched donor was
determined by calculating the percentage of patients with at least
one matched donor (6 of 6 antigens). Data analyses were done using SPSS
16.0 (SPSS, Inc., Chicago, IL).RESULTS
Patient Characteristics
A total of 1254 consecutive patients examined at KHCC
between 2003 and 2011 were analyzed retrospectively. Each
screened patient was assigned to the adult (age>18 years) or
pediatric group, and each group was further subdivided into
age groups. Characteristics of the 1254 patients included in
the study are presented in Table 1. The majority of patients
(65%) were age<18 years, with the largest disease-conﬂicted
group clustered at age 6-12 years (45%). Similarly, a signiﬁ-
cantly high percentage of adult patients (60%) were clustered
in the 18-35 year group. Males were predominant over
females in both the pediatric and adult groups (57.5% versus
42.5% and 61% versus 39%, respectively). Overall, for all
patients, the probability of having an HLA-matched donor
was 65%, with a higher value in adults (74%) compared with
the pediatric group (60.6%).Probability of Finding a Matched Donor
We ﬁrst analyzed the family size of overall patients to
identify any correlation with donor availability. We found no
signiﬁcant differences in median family size between
patients with at least 1 matched donor and those without
a matched donor (Table 2). In other words, donor availability
was not correlated with immediate family size.
We divided the adult and pediatric groups into 3 age
subgroups each. We analyzed donor availability for each age
group and compared the overall respective pediatric and
adult results. In the pediatric group, therewas a trend toward
an increasing percentage of patients with an HLA-matched
donor with increasing patient age (Table 3). The adult
group overall exhibited a similar trend of donor availability,but subgroup 6 patients (age >50 years) had a signiﬁcantly
lower percentage of patients with an HLA-matched donor
(67%) comparedwith subgroups 4 and 5 and the overall adult
availability of 74% (Table 4). In the pediatric group, the
average number of available donors was almost identical in
subgroups 1, 2, and 3 (1.35, 1.4, and 1.4 donors per patient,
respectively) (Table 3). In contrast, adult patients had an
average of 1.6 matched donors for subgroup 4, 1.8 for
subgroup 5, and 1.5 for subgroup 6 (Table 4). The slightly
higher average numbers of HLA-matched donors in the
adults in contrast to the pediatric group is reﬂected in the
higher percentage of donor availability for adult patients
overall (74%) compared with the pediatric group overall
(60.6%).
Donor source was categorized as HLA-matched sibling,
nonsibling (including parents and all related family
members), or extended-family donor (including blood-
related noneimmediate family members only). Interest-
ingly, 18% of overall HLA-matched donors were nonsibling
blood relatives, with 17% of them noneimmediate family
members (Table 3). In contrast, only 6% of all HLA-matched
donors were nonsibling related in the adult group
(Table 4). The distribution of HLA-identical sibling donors
versus related immediate or extended family donors did not
differ among the pediatric and adult subgroups.HLA Phenotype and Haplotype Frequencies in the
Jordanian Population
The frequencies of HLA-A, -B, and -DR are presented in
Table 5. A total of 20 HLA-A antigens, 30 HLA-B antigens, and
20 HLA-DR antigens were detected. The most frequent
HLA-A locus was HLA-A*02 (21.3%), followed by HLA-A*01
(15%) and then HLA-A*24 (10.4%). The antigens detected at
the highest frequencies for the HLA-B locus were HLA-B*35
(14%), HLA-B*51 (9.9%), HLA-B*49 (6.7%), and HLA-B*50
(6.6%). Data analysis identiﬁed the 3 most prevalent DRB1*
phenotypes in the study group as DRB1*11, DRB1*04, and
DRB1*13, with respective frequencies of 20.6%, 16.2%, and
14.4%. The most frequent haplotypes seen in the Jordanian
population are listed in Table 6: HLA-A*02-B*50-DR*07
(0.039), HLA-A*02-B*51-DR*04 (0.028), and HLA-A*24-B*35-
DR*11 (0.023).
Table 7 compares gene frequencies for HLA-A, -B, and -DR
among different ethnic populations. As expected, the gene
frequency pattern of the Jordanian population is more closely
related to the patterns reported in Saudi Arabians [9], Turks
[10], and some Caucasians [8,11] than to the patterns of
Indians [12,13] and Asians [8,11]; however, Jordanians have
higher gene frequencies of A*01, A*30, B*35, and B*49.
Table 3
Probability of Finding a Matched Donor in Pediatric Patients by Age Group
Donor Availability Entire Age Group 0-5 Years (Group 1) 6-12 Years (Group 2) 13-18 Years (Group 3)
n (%) Mean  SD Range n (%) Mean  SD Range n (%) Mean  SD Range n (%) Mean  SD Range
Patients without donors 321 (39.4) 105 (43) 149 (41) 67 (33)
Patients with donors 494 (60.6) 1.4  0.9 1-7 141 (57) 1.35  1 1-7 215 (59) 1.4  0.7 1-5 138 (67) 1.4  0.6 1-6
Patients with sibling
donors
407 (82) 1.45  0.7 1-6 115 (82) 1.32  0.6 1-3 180 (84) 1.4  0.8 1-5 112 (81) 1.4  0.6 1-6
Patients with non-sibling
donors
87 (18) 1.5  0.5 1-4 26 (18) 1.37  1.2 1-7 35 (16) 1.4  0.6 1-3 26 (19) 1.6  0.8 1-3
Patients with extended
family donors
15 (17) 2  1.6 1-7 4 (15) 2.5  3 1-7 9 (25) 1.8  0.8 1-3 4 (15) 2  1 1-3
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Jordan has a population of approximately 5.6 million. The
high rate of consanguineous marriage and environmental
factors contribute to a high rate of genetic malignant and
nonmalignant diseases that can be treated by HSCT, for
which donors are required. Bone marrow and stem cell
transplantation has been performed in Jordan since the early
1990s, but the ﬁrst comprehensive program was not estab-
lished until March 2003, at KHCC [14].
This is the ﬁrst study to address the probability of ﬁnding
HLA-matched related donors for Jordanian patients awaiting
HSCT at KHCC. Overall, 65.5% of our patients had an identical
HLA-matched blood-related donor (60.6% in the pediatric
group and 74% in adults). Of the 377 patients who underwent
matched related allo-HSCT at KHCC between January 2003
and the end of December 2011, 349 (92.5%) had a matched
sibling donor (190 [77%] in the pediatric group) and 28 (7.5%)
had a nonsibling family donor (26 [93%] in the pediatric
group).
The high probability of ﬁnding amatched related donor in
the Jordanian pool donor is higher than what has been re-
ported in international searches for matched unrelated
donors (MUDs), especially for Caucasian populations.
Approximately 15 million international HSCT donors are
currently registered in a network of interconnected hubs
(National Hematopoietic Stem Cell Donor Registries [7,15]. In
2008, only 50%-60% of patients of Caucasian descent had
a fully HLA-matched and available unrelated adult donor,
and non-Caucasians had a substantially lower probability
[16]. Indeed, according to data from the National Marrow
Donor Program, only roughly 20% of Asians and 17% of
African Americans will ﬁnd a fully HLA-matched and avail-
able unrelated adult donor [16]; however, in Austria, the
likelihood of identifying a suitable MUD for patients is
reportedly 68.9% [7]. This high success rate in the donor
search for patients of Austrian descent is likely attributed to
the small Austrian ethnic population pool, which increasesTable 4
Probability of Finding a Matched Donor in Adult Patients by Age Group
Donor Availability Entire Age Group 18-35 Years (Grou
n (%) Mean  SD Range n (%) Mean 
Patients without donors 112 (26) 65 (25)
Patients with donors 327 (74) 1.6  0.9 1-5 197 (75) 1.6  0.
Patients with sibling
donor
308 (94) 1.7  0.6 1-5 186 (94) 1.6  0.
Patients with non-sibling
donor
19 (6) 1.4  0.5 1-2 11 (6) 1.6  0.
Patients with extended
family donor
6 (32) 1.3  0.5 1-2 3 (27) 1.3  0.the chance of ﬁnding an MUD. Similarly, Heemskerk et al.
[17] reported that over the last 10 years, an unrelated donor
could be found for 84% of HSCT recipients in a mainly Dutch
patient population. The Jordanian population comprises 98%
Arabs, 1% Circassians, and 1% Armenians, and overall can be
considered to represent a single major ethnic group inwhich
a potential MUD exists for the patients with no donor. It is
possible that patients of ethnic minority have a smaller pool
of registered marrow donors in international registries.
Indeed, the chance of ﬁnding a matched HSCT donor for
a Jordanian patient from the international unrelated stem
cell registries is only 2%-5%. Other potential factors that may
contribute to the low matched donor availability are the
decline in consanguineous marriages (w23%) and decrease
in family size (w41%) seen in Jordan over the last decade [7].
As would be expected, increasing family size increases the
likelihood of identifying an HLA-matched donor. This is re-
ﬂected in our patient data, with a greater chance of ﬁnding
a donor seen in the older age subgroups. However, the
decline in consanguineous marriage rate and family size
could have a constrictive effect on the likelihood of identi-
fying a matched related donor, by diminishing the necessary
combinations of HLA determinants found in the patients.
This can be rectiﬁed by establishing a national donor registry
in Jordan, to increase the chance of identifying a MUD for
patients with no donor and patients of ethnic minorities or
mixed ancestries.
In a Saudi study, Jawdat et al. [3] examined different
variables for possible associations with the increased likeli-
hood of ﬁnding an HLA-matched sibling donor in older
patients. Similar to their results, our ﬁndings showed no
correlation with sex (data not shown). However, based on
the observed increased likelihood of ﬁnding a matched
donor in adult and pediatric groups, our ﬁndings support
that older patient age is associated with an increasing
number of siblings to screen. Indeed, the likelihood of ﬁnding
a matched donor was greater in patients age 18-35 yearsp 4) 36-50 Years (Group 5) >50 Years (Group 6)
SD Range n (%) Mean  SD Range n (%) Mean  SD Range
32 (24) 15 (33)
6 1-5 99 (76) 1.8  0.6 1-5 31 (67) 1.5  0.6 1-3
9 1-5 93 (94) 1.8  0.8 1-5 29 (94) 1.5  0.6 1-3
6 1-3 6 (6) 1.5  0.5 1-2 2 (6) 1  0 1
5 1-2 2 (33) 1.5  0.7 1-2 1 (50) d d
Table 5
Frequency of HLA-A, -B and DR Antigens in the Jordanian Population
HLA-A Number Frequency, % HLA-B Number Frequency, % HLA-DR Number Frequency, %
01 354 14.7 07 67 2.7 01 109 4.8
02 532 22.0 08 57 2.3 03 276 12.1
03 219 9.1 13 71 2.9 04 382 16.7
11 103 4.3 14 107 4.4 07 242 10.6
23 96 4.0 15 114 4.7 08 52 2.3
24 259 10.7 18 130 5.3 09 8 0.3
25 4 0.2 27 40 1.6 10 63 2.8
26 126 5.2 35 365 14.9 11 482 21.1
29 62 2.6 37 17 0.7 12 23 1.0
30 219 9.1 38 114 4.7 13 332 14.5
31 55 2.3 39 39 1.6 14 86 3.8
32 73 3.0 40 54 2.2 15 211 9.2
33 81 3.4 41 142 5.8 16 20 0.9
34 19 0.8 42 22 0.9
36 4 0.2 44 137 5.6
43 0 0.0 45 40 1.6
66 20 0.8 46 1 0.0
68 121 5.0 47 12 0.5
69 46 1.9 48 0 0.0
74 19 0.8 49 153 6.2
80 3 0.1 50 157 6.4
51 252 10.3
52 119 4.9
53 50 2.0
54 1 0.0
55 31 1.3
56 6 0.2
57 78 3.2
58 57 2.3
59 0 0.0
67 0 0.0
73 15 0.6
78 0 0.0
81 0 0.0
82 1 0.0
83 0 0.0
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likelihood of ﬁnding a matched donor is greater in the older
patients in both the pediatric and adult groups.
Previous studies have shown equivalent survival in
patients with hematologic malignancies who underwent
HSCT with a graft from a related donor who was pheno-
typically HLA-matched and those who did so with a graft
from a genotypically HLA-matched sibling [18]. In our insti-
tution, for patients lacking an HLA-identical sibling donor orTable 6
Haplotype Frequencies in the Jordanian Population
Haplotype Frequency
HLA-A*02 B*50 DR*07 0.0386
HLA-A*02 B*51 DR*04 0.0276
HLA-A*24 B*35 DR*11 0.0234
HLA-A*24 B*18 DR*11 0.0193
HLA-A*01 B*35 DR*11 0.0166
HLA-A*24 B*35 DR*04 0.0152
HLA-A*02 B*41 DR*04 0.0138
HLA-A*03 B*51 DR*11 0.0138
HLA-A*33 B*14 DR*04 0.0138
HLA-A*30 B*49 DR*13 0.0124
HLA-A*30 B*53 DR*13 0.0124
HLA-A*29 B*18 DR*04 0.0124
HLA-A*02 B*35 DR*11 0.0124
HLA-A*03 B*51 DR*07 0.0124
HLA-A*01 B*52 DR*04 0.0110
HLA-A*11 B*35 DR*04 0.0110
HLA-A*02 B*51 DR*11 0.0110
HLA-A*11 B*52 DR*15 0.0110
HLA-A*24 B*15 DR*13 0.0110other immediate family donor (ie, parent), an extended
family search is pursued simultaneously with a search for an
unrelated donor. Jawdat et al. [3] reported no correlation
between consanguineous marriage and ﬁnding a matched
sibling donor; however, at our center, 13% of potential
HLA-matched donors are from the immediate or
extended family, with the highest number in the 13- to
18-year age group. To our knowledge, the literature contains
no data regarding the actual likelihood of ﬁnding an
HLA-matched donor in the patient’s immediate or extended
family.
Schipper et al. [19] developed a procedure for calculating
the probability of ﬁnding a suitable donor among a patient’s
extended family. This procedure relies on a large extended
family, which applies to the Jordanian population, and on the
frequencies of haplotypes involved. At our center, we strive
to deduce the family tree of patients to pinpoint potential
extended family donors, as evidenced by the signiﬁcant
number of blood-related donors identiﬁed. Another perti-
nent consideration is that our results are based on the
number of donors tested at our center, which might not
reﬂect the true number of blood-related donors, suggesting
an even higher likelihood of ﬁnding extended family donors.
Comparing our reported HLA class I and II proﬁles with
those reported from Saudi Arabia [9], Turkey [10], India
[12,13], Caucasian populations [8,11], and Asians reveals that
the Jordanian pool is generally more closely related to the
Saudi and Turkish populations. Overall, these observations
are consistent with recognized historical, geographical,
cultural, ethnic, and linguistic relationships among these
Table 7
Comparison of Main Gene Frequencies of HLA Phenotypes in Jordan and Other Ethnic Populations
HLA Jordan Saudi Arabia Turkey India Caucasian Asian
HLA-A (n ¼ 2415) (n ¼ 383) (n ¼ 228) (n ¼ 91) (n ¼ 265) (n ¼ 358)
02 22.0 30.4 21.9 9.6 27.1 9.5
01 14.7 6.8 6.6 12.3 15.1 1.5
24 10.7 6.7 21.3 16.7 6.6 18.9
03 9.1 6.3 10.9 9.3 12.6 1.0
30 9.1 5.2 1.3 1.1 1.1 1.8
HLA-B (n ¼ 2449) (n ¼ 383) (n ¼ 228) (n ¼ 91) (n ¼ 265) (n ¼ 358)
35 14.9 8.2 14 5.6 6.8 3.9
51 10.3 12.8 15.8 6.8 5.7 6.7
50 6.4 3.3 6.6 0.7 0.6 0
49 6.2 18.8 5 3.6 0.9 0.1
41 5.8 3.5 13.4 10.5 11.7 4.4
HLA-DR (n ¼ 2286) (n ¼ 383) (n ¼ 228) (n ¼ 102) (n ¼ 232) (n ¼ 232)
11 21.1 7.8 35.4 17.7 9.7 8.3
04 16.7 18.9 13.1 8.8 12.8 14.4
13 14.5 13.8 6.2 15.2 12.7 3.0
03 12.1 15.4 9.6 10.3 10.1 2.9
07 10.6 17.8 11.7 8.8 15.1 16.3
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a greater likelihood of ﬁnding a phenotypically matched
donor in registries based on these populations. Furthermore,
to date only 1 study has examined HLA proﬁles in the Jor-
danian population: a survey by Sánchez-Velasco et al. [20] of
a small pool of 100 adults from Amman and 46 adults from
the Jordan River valley. In the present study, we examined
a signiﬁcantly larger pool of Jordanians from various regions
of the country. In contrast to our data, Sánchez-Velasco
et al. [20] reported themost frequent HLA-A loci as HLA-A*02
(13.4%), HLA-A*30 (9.3%), HLA-A*01 (7.9%), HLA-A*11 (7.9%),
and HLA-A*24 (5.9%). Although 4 of these phenotypes were
also among the top 5 most observed in our data, A*11 (4.3%)
was not identiﬁed as such. For HLA-B, Sánchez-Velasco
et al. [20] identiﬁed B*07 as the most frequent locus (17.2%),
followed by B*35 (8.3%), B*51 (6.6%), B*08 (3.8%), and B*44
(2.8%). We identiﬁed B*35 as the most frequent locus in our
Jordanian population, but found no signiﬁcant frequency of
B*07 or B*08. Finally, Sánchez-Velasco et al. identiﬁed the
most frequent DRB1 allele in their Jordanian population as
DRB1*07 (25.5%), followed by DRB1*04 (19.7%), and DRB1*15
(8.9%). In our much larger population pool, DRB1*11 was the
most frequently detected locus; DRB1*15 frequency was
9.2%, comparable to that reported by Sánchez-Velasco et al.
Overall, the high prevalence of gene frequencies reported by
our group and by Sánchez-Velasco et al. [20] can be
explained by the continued high frequency of consanguin-
eous marriages in Jordan.
The most common HLA-A-B-DRB haplotype in our Jor-
danian population was HLA-A*02-B*50-DR*07 (3.9%), which
is also very common in Tunis (3%) and United Arab Emirates
(4.8%) [21]. This haplotype also has been reported in
Mongolians (3.2%), Manchu (2.2%), Spaniards (1.2%), and
Italians (0.5%) [21]. The HLA-A*02-B*51-DR*04 haplotype
was identiﬁed in 2.8% of our study population, compared
with 7.2% of the Pakistani population but<0.1% of Caucasians
in western Europe [22]. The 2.3% frequency of HLA-A*24-
B*35-DR*11 in our population is comparable to that re-
ported in Austrians (2.7%), Germans (1.4%), and Italians (1.4%)
[21], but signiﬁcantly lower than that reported in Georgians
(5.7%) [23]. Finally, the HLA-A*24 B*18 DR*11 haplotype was
identiﬁed in 1.9% of our population, compared with 2.1% of
Armenians and 0.7% of Italians [21]. The low occurrence of
the most common Jordanian haplotypes in other populations
reiterates again the critical need for a local donor registry.The probability of ﬁnding an MUD in national and interna-
tional registries is dependent on the frequency of haplotypes
among different populations. This is evident from the patient
and donor lists in our center, in which patients without
a matching related donor have an only 1 in 50 chance of
ﬁnding a MUD in European donor registries. Taking into
consideration the geographical and cultural similarities
between Jordan and its neighboring Arabic countries,
a higher likelihood of ﬁnding a MUD in established donor
registries of Arabic origin will be a better alternative for both
Jordan and its neighbors.
In conclusion, our Jordanian patients’ chance of ﬁnding an
HLA-matched donor appears to be high because of the
increased probability of ﬁnding an identical donor in the
immediate and extended families. A future study will
compare clinical outcomes in recipients of HSCT with
a related donor and those with a genotypically HLA-matched
sibling. Our conclusions are strengthened by the fact that this
is a population-based, single-center study with a relatively
large number of patients and donors. Our data conﬁrm the
feasibility of using HLA-related donors to avoid lengthy
matching procedures and provide patients with identical
haplotypes instead of merematching at the phenotypic level.
Furthermore, HLA typing of extended family donors along
with immediate family and sibling donors can provide the
transplant physician with more ﬂexibility in ﬁnal donor
selection and identiﬁcation of a readily available backup
matched donor. Thus, we recommend integrating donor
search process in the extended family concomitant with an
unrelated donor search. This recommendation also can be
applied to Western subpopulations whose origin descends
from ethnic groups with a similar pattern as the Jordanian
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